These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34129638)

  • 1. Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK.
    Stuurman AL; Ciampini S; Vannacci A; Bella A; Rizzo C; Muñoz-Quiles C; Pandolfi E; Liyanage H; Haag M; Redlberger-Fritz M; Bonaiuti R; Beutels P
    PLoS One; 2021; 16(6):e0252836. PubMed ID: 34129638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform.
    Stuurman AL; Biccler J; Carmona A; Descamps A; Díez-Domingo J; Muñoz Quiles C; Nohynek H; Rizzo C; Riera-Montes M;
    Vaccine; 2021 Jun; 39(29):3964-3973. PubMed ID: 34092427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform.
    Stuurman AL; Carmona A; Biccler J; Descamps A; Levi M; Baum U; Mira-Iglesias A; Bellino S; Hoang U; de Lusignan S; Bonaiuti R; Lina B; Rizzo C; Nohynek H; Díez-Domingo J;
    Front Public Health; 2023; 11():1195409. PubMed ID: 37546295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives.
    de Fougerolles TR; Baïssas T; Perquier G; Vitoux O; Crépey P; Bartelt-Hofer J; Bricout H; Petitjean A
    BMC Public Health; 2024 May; 24(1):1222. PubMed ID: 38702667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of coverage and analysis of the determinants of adherence to influenza vaccination in the general practitioners of Taranto.
    Desiante F; Caputi G; Cipriani R; Nanula C; Aprile I; Pesare A; Conversano M
    Ann Ig; 2017; 29(4):256-263. PubMed ID: 28569335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the procurement system for understanding seasonal influenza vaccine brand availability in Europe.
    Stuurman AL; Rizzo C; Haag M
    PLoS One; 2021; 16(4):e0248943. PubMed ID: 33831021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19.
    Stuurman AL; Bollaerts K; Alexandridou M; Biccler J; Díez Domingo J; Nohynek H; Rizzo C; Turunen T; Riera-Montes M;
    Vaccine; 2020 Sep; 38(41):6455-6463. PubMed ID: 32778474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity of Circulating Influenza Viruses and Their Impact on Influenza Virus Vaccine Effectiveness During the Influenza Seasons 2016/17 to 2018/19 in Austria.
    Redlberger-Fritz M; Kundi M; Popow-Kraupp T
    Front Immunol; 2020; 11():434. PubMed ID: 32256493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.
    Kissling E; Valenciano M; Larrauri A; Oroszi B; Cohen JM; Nunes B; Pitigoi D; Rizzo C; Rebolledo J; Paradowska-Stankiewicz I; Jiménez-Jorge S; Horváth JK; Daviaud I; Guiomar R; Necula G; Bella A; O'Donnell J; Głuchowska M; Ciancio BC; Nicoll A; Moren A
    Euro Surveill; 2013 Jan; 18(5):. PubMed ID: 23399425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy.
    Bonanni P; Boccalini S; Zanobini P; Dakka N; Lorini C; Santomauro F; Bechini A
    Hum Vaccin Immunother; 2018 Mar; 14(3):699-705. PubMed ID: 29059004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013-14: Results from the InNHOVE network.
    Rondy M; Castilla J; Launay O; Costanzo S; Ezpeleta C; Galtier F; de Gaetano Donati K; Moren A
    Hum Vaccin Immunother; 2016 May; 12(5):1217-24. PubMed ID: 27065000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons.
    Blank PR; Schwenkglenks M; Szucs TD
    J Infect; 2009 Jun; 58(6):446-58. PubMed ID: 19446340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy.
    Bellino S; Bella A; Puzelli S; Di Martino A; Facchini M; Punzo O; Pezzotti P; Castrucci MR; The InfluNet Study Group
    Expert Rev Vaccines; 2019 Nov; 18(11):1201-1209. PubMed ID: 31674847
    [No Abstract]   [Full Text] [Related]  

  • 14. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15.
    Gherasim A; Pozo F; de Mateo S; Gamarra IA; García-Cenoz M; Vega T; Martínez E; Giménez J; Castrillejo D; Larrauri A;
    Vaccine; 2016 Apr; 34(20):2371-7. PubMed ID: 27020713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine effectiveness of live attenuated and trivalent inactivated influenza vaccination in 2010/11 to 2015/16: the SIVE II record linkage study.
    Simpson CR; Lone NI; Kavanagh K; Englishby T; Robertson C; McMenamin J; Wissman BV; Vasileiou E; Butler CC; Ritchie LD; Gunson R; Schwarze J; Sheikh A
    Health Technol Assess; 2020 Dec; 24(67):1-66. PubMed ID: 33256892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons.
    Szucs TD; Müller D
    Vaccine; 2005 Oct; 23(43):5055-63. PubMed ID: 16046035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2012-2013 Seasonal influenza vaccine effectiveness against influenza hospitalizations: results from the global influenza hospital surveillance network.
    Puig-Barberà J; Natividad-Sancho A; Launay O; Burtseva E; Ciblak MA; Tormos A; Buigues-Vila A; Martínez-Úbeda S; Sominina A;
    PLoS One; 2014; 9(6):e100497. PubMed ID: 24945510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriateness and preferential use of different seasonal influenza vaccines: A pilot study on the opinion of vaccinating physicians in Italy.
    Boccalini S; Tacconi FM; Lai PL; Bechini A; Bonanni P; Panatto D
    Vaccine; 2019 Feb; 37(7):915-918. PubMed ID: 30651199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific vaccination coverage estimates for influenza, human papillomavirus and measles containing vaccines from seven population-based healthcare databases from four EU countries - The ADVANCE project.
    Braeye T; Emborg HD; Llorente-García A; Huerta C; Martín-Merino E; Duarte-Salles T; Danieli G; Tramontan L; Weibel D; McGee C; Villa M; Gini R; Lehtinen M; Titievsky L; Sturkenboom M
    Vaccine; 2020 Apr; 38(16):3243-3254. PubMed ID: 32171573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.
    Müller D; Szucs TD
    Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.